Fundraising Fox

Adelabio

Foster City, US · Founded 2020 · 71 employees on LinkedIn · 5 known investors

Find your way into Adelabio

126 people in our graph share verified history with the Adelabio team — schools, employers, funds. One of them is your warm intro.

Kate Mitchellunlockedknows Anne-Renee Hartman · together at Operator Collective (overlapped)
×9knows the team · via Operator Collective
×2knows the team · via Dana Farber Cancer Institute

Adela develops blood-based tests for cancer detection using epigenetics and liquid biopsy technology, aimed at helping patients and clinicians detect and act on cancer earlier. It serves the oncology and cancer care market.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

Adelabio was founded in 2020 by Daniel Diniz De Carvalho, Scott Bratman, and Anne-Renee Hartman.

DD
Daniel Diniz De CarvalhoCo-founder
SBScott Bratman
Scott BratmaninCo-Founder
AHAnne-Renee Hartman
Anne-Renee HartmaninCo-founder and Chief Medical OfficerAnne-Renee Hartman is founder of Adela, which develops blood-based cancer detection tests using epigenetics and liquid biopsy technology. She has 15+ years of experience in molecular diagnostics.
AWAlan Williams
Alan WilliamsinChief Operations Officer
LALisa Alderson
Lisa AldersoninChief Executive Officer and President2023–2026
PHPriscilla Huang
Priscilla HuanginSenior Vice President Finance2020–2025
KJKarla Jarvis
Karla JarvisinExecutive
MJ
Maneesh JainNamed on SEC filing
AH
Anne-Renee Hartman FeldmanNamed on SEC filing

Board

AEAndrew ElBardissi
Andrew ElBardissiin𝕏Board MemberPartner at Deerfield Management Company
DBDavid Bonita
David BonitainBoard directorInvestor at OrbiMed
PB
Paul BrownBoard director

Investors · 5

Decheng CapitalMenlo Park
F-Prime CapitalCambridge · $3M – $10M
OrbiMedNew York · $1M – $75M
Deerfield Management Companyreported · 2 sourcesNew Yorkvia Andrew ElBardissi · board
Menlo VenturesreportedSan Francisco · $1M – $20M

Reported raises · per SEC filings

Form D private placements

$113.5M disclosed across 6 rounds · 2021–2026

▶$5MraisedApr 2026 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert WeisskoffDirector
  • Alan WilliamsExecutive Officer
  • Daniel Diniz De CarvalhoExecutive Officer
  • Paul BrownDirector
  • Maneesh JainDirector
  • David ScheerExecutive Officer, Director
  • Abraham KometzDirector
  • David BonitaDirector
  • Scott BratmanExecutive Officer
  • Anne-Renee HartmanExecutive Officer
  • Lisa AldersonExecutive Officer, Director
  • Lindsay MateoExecutive Officer
Offering amount
$5M
Amount sold
$5M
First sale
Apr 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25.4MraisedJul 2025 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lisa AldersonExecutive Officer, Director
  • Anne-Renee HartmanExecutive Officer
  • Andrew ElBardissiDirector
  • David BonitaDirector
  • Maneesh JainDirector, Promoter
  • Robert WeisskoffDirector
  • Paul BrownDirector
  • Daniel Diniz De CarvalhoExecutive Officer, Promoter
  • Alan WilliamsExecutive Officer
  • David ScheerExecutive Officer, Director, Promoter
  • Priscilla HuangExecutive Officer
Offering amount
$27M
Amount sold
$25.4M
First sale
Jun 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$48.5MraisedJul 2024 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew ElBardissiDirector
  • David BonitaDirector
  • Paul BrownDirector
  • Anne-Renee HartmanExecutive Officer
  • Alan WilliamsExecutive Officer
  • David ScheerExecutive Officer, Director, Promoter
  • Lisa AldersonExecutive Officer, Director
  • Priscilla HuangExecutive Officer
  • Karla JarvisExecutive Officer
  • Robert WeisskoffDirector
  • Maneesh JainDirector, Promoter
  • Daniel Diniz De CarvalhoExecutive Officer, Promoter
Offering amount
$49.3M
Amount sold
$48.5M
First sale
Jul 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedFeb 2024 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew ElBardissiDirector
  • Daniel Diniz De CarvalhoExecutive Officer, Promoter
  • Maneesh JainDirector, Promoter
  • Anne-Renee HartmanExecutive Officer
  • Priscilla HuangExecutive Officer
  • Robert WeisskoffDirector
  • Lisa AldersonExecutive Officer, Director
  • Alan WilliamsExecutive Officer
  • Paul BrownDirector
  • David ScheerExecutive Officer, Director, Promoter
  • David BonitaDirector
  • Karla JarvisExecutive Officer
Offering amount
$1.2M
Amount sold
$1.2M
First sale
Jul 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.3MraisedFeb 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David ScheerExecutive Officer, Director, Promoter
  • Andrew ElBardissiDirector
  • Lisa AldersonExecutive Officer, Director
  • David BonitaDirector
  • Karla JarvisExecutive Officer
  • Anne-Renee HartmanExecutive Officer
  • Maneesh JainDirector, Promoter
  • Robert WeisskoffDirector
  • Alan WilliamsExecutive Officer
  • Daniel Diniz De CarvalhoExecutive Officer, Promoter
  • Paul BrownDirector
  • Priscilla HuangExecutive Officer
Offering amount
$3.3M
Amount sold
$3.3M
First sale
Oct 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30MraisedMar 2021 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Anne-Renee Hartman FeldmanExecutive Officer
  • Daniel De CarvalhoExecutive Officer
  • Maneesh JainDirector
  • Scott BratmanExecutive Officer, Director
  • David ScheerDirector
Offering amount
$60M
Amount sold
$30M
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Medical firm Adela raises US$48M investment to advance tech developed in Toronto - The Logicthelogic.co · Sep 2023Adela Raises $48M in Financingfinsmes.com · Sep 2023Adela Raises $60M in Series A Fundingfinsmes.com · Jun 2021Cancer detection startup spun out of Toronto’s UHN raises $60-million from top US biotech investors - The Globe and Mailtheglobeandmail.com · Jun 2021Toronto biotech startup Adela raises $60-million from top U.S. investors — OBIOobio.ca · Jun 2021DHN - Adela Health Raises $48Mn Funding to Boost Cancer Detection Technologiesdigitalhealthnews.com

Frequently asked questions

What does Adelabio do?
Adela develops blood-based tests for cancer detection using epigenetics and liquid biopsy technology, aimed at helping patients and clinicians detect and act on cancer earlier. It serves the oncology and cancer care market.
Who founded Adelabio?
Adelabio was founded by Daniel Diniz De Carvalho, Scott Bratman, Anne-Renee Hartman in 2020.
Who are Adelabio's investors?
Adelabio's investors include Decheng Capital, F-Prime Capital, OrbiMed, Deerfield Management Company, Menlo Ventures.
How much funding has Adelabio raised?
Adelabio has disclosed $113.5M raised across 6 rounds.
Where is Adelabio headquartered?
Adelabio is headquartered in Foster City, US.